Greg Mayes (Engage)

Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M up­front

UCB has picked up an epilep­sy drug-de­vice from a buy­out that will cost at most $270 mil­lion, tuck­ing a Phase III-ready project and the team …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.